Merck’s deepening collaboration with Moderna on the intismeran autogene mRNA cancer vaccine plus Keytruda has produced a positive Phase 3 readout in melanoma, yet this has not translated into merger or acquisition activity. The companies maintain a long-standing 50/50 cost-and-profit-sharing arrangement established in 2016, and recent trial success has lifted both share prices without prompting a change-of-control transaction. Merck has instead pursued separate deals, including the $6.7 billion Terns Pharmaceuticals acquisition and the $11.3 billion Bio-Techne agreement slated for late-2026 or early-2027 closure. With only three-and-a-half months remaining in 2026 and no regulatory filings, board discussions, or material disclosures indicating an impending Moderna takeover, market-implied odds heavily favor no announcement by year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於是
24% 機率
最新
最新
2026-12-31
是
24% 機率
最新
最新
2026-12-31
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck’s deepening collaboration with Moderna on the intismeran autogene mRNA cancer vaccine plus Keytruda has produced a positive Phase 3 readout in melanoma, yet this has not translated into merger or acquisition activity. The companies maintain a long-standing 50/50 cost-and-profit-sharing arrangement established in 2016, and recent trial success has lifted both share prices without prompting a change-of-control transaction. Merck has instead pursued separate deals, including the $6.7 billion Terns Pharmaceuticals acquisition and the $11.3 billion Bio-Techne agreement slated for late-2026 or early-2027 closure. With only three-and-a-half months remaining in 2026 and no regulatory filings, board discussions, or material disclosures indicating an impending Moderna takeover, market-implied odds heavily favor no announcement by year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
市場開放時間： Aug 19, 2026, 3:58 PM ET
交易量
$458結束日期
2027-01-01市場開放時間
Aug 19, 2026, 3:58 PM ETThis market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck’s deepening collaboration with Moderna on the intismeran autogene mRNA cancer vaccine plus Keytruda has produced a positive Phase 3 readout in melanoma, yet this has not translated into merger or acquisition activity. The companies maintain a long-standing 50/50 cost-and-profit-sharing arrangement established in 2016, and recent trial success has lifted both share prices without prompting a change-of-control transaction. Merck has instead pursued separate deals, including the $6.7 billion Terns Pharmaceuticals acquisition and the $11.3 billion Bio-Techne agreement slated for late-2026 or early-2027 closure. With only three-and-a-half months remaining in 2026 and no regulatory filings, board discussions, or material disclosures indicating an impending Moderna takeover, market-implied odds heavily favor no announcement by year-end.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
交易量
$458結束日期
2027-01-01市場開放時間
Aug 19, 2026, 3:58 PM ETMerck’s deepening collaboration with Moderna on the intismeran autogene mRNA cancer vaccine plus Keytruda has produced a positive Phase 3 readout in melanoma, yet this has not translated into merger or acquisition activity. The companies maintain a long-standing 50/50 cost-and-profit-sharing arrangement established in 2016, and recent trial success has lifted both share prices without prompting a change-of-control transaction. Merck has instead pursued separate deals, including the $6.7 billion Terns Pharmaceuticals acquisition and the $11.3 billion Bio-Techne agreement slated for late-2026 or early-2027 closure. With only three-and-a-half months remaining in 2026 and no regulatory filings, board discussions, or material disclosures indicating an impending Moderna takeover, market-implied odds heavily favor no announcement by year-end.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions